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Enzyme replacement therapy reduces the
risk for wheelchair dependency in adult
Pompe patients
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Abstract
Background: Pompe disease is a rare metabolic myopathy. In adult patients, progressive weakness of limb-girdle
and respiratory muscles often leads to wheelchair and respirator dependency. Clinical studies have shown enzyme
replacement therapy (ERT) to positively affect motor and respiratory outcomes. Here we investigate whether ERT
reduces patients’ risk of needing a wheelchair or respirator.
Methods: Data were collected as part of a prospective international survey, the IPA/Erasmus MC Pompe survey,
which was conducted annually between 2002 and 2016. We excluded patients who were already using a
wheelchair or respirator, those under 18 at survey entry, and those who had missing information. Time-dependent Cox
proportional hazard models were used.
Results: The inclusion criteria for analyzing the risk of wheelchair use were met by 189 patients (median age 47 years;
range 18–75). During follow-up, 126 (67%) started ERT. Over 1120 person-years of follow-up (median 5 years),
46 became wheelchair dependent, 16 of whom used ERT. After adjustment for disease duration, sex and country,
ERT reduced the risk for wheelchair use (HR 0.36; 95% CI 0.17–0.75). For analyses of respirator use, 177 patients met the
inclusion criteria (median age 46 years; range 18–73). Over 1190 person-years of follow-up (median 6 years), 125
patients (71%) were treated and 48 started respiratory support, 28 of whom received ERT. We found no association
between ERT and the risk for respirator use (HR 1.23; 95% CI 0.61–2.47).
Conclusions: Our study found that ERT reduced the risk for wheelchair dependency. We could not demonstrate an
effect on respiratory support.
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Background
Pompe disease is an autosomal recessive metabolic myop-
athy for which enzyme replacement therapy (ERT) with
alglucosidase alfa has been available since 2006 [1, 2]. In
adults, the disease is characterized by progressive limb-
girdle and respiratory muscle weakness. In most cases, this
ultimately leads to the use of a wheelchair and/or respira-
tory support [3, 4]. Wheelchair dependency and the use of
respiratory support considerably impact a patient’s ability
to participate in daily life activities, and reduce quality of
life [5, 6]. It should therefore be an important treatment
goal to prevent the disease from progressing to the point
that a patient becomes dependent on these aids.
Many studies have evaluated the effects of ERT in
adult patients with Pompe disease. While these have
shown that ERT has a positive effect on motor function
and/or lung function [7–15], its effect on wheelchair
dependency and respiratory support has been reported
only in a few cases.
Together with the International Pompe Association
(IPA), our center has systematically collected data on
patients with Pompe disease since 2002, well before the
approval of ERT. This IPA/Erasmus MC Pompe survey
has consistently followed a large international cohort of
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patients over many years, both before and during ERT.
Earlier findings from the survey include the demonstra-
tion of a positive effect of ERT on survival [16]. Using
data from this survey, we investigated whether ERT




A detailed description of the survey’s design has been
published previously [16]. Since 2002, patients have been
recruited through national patient organizations in
Canada, Germany, France, the Netherlands, the United
Kingdom and the United States. Recruitment was inde-
pendent of patients’ disease severity. All patients have
provided informed consent.
Annual survey questions included items on the use of
a wheelchair and respiratory support. Disease duration
was calculated as the number of years since diagnosis. In
our analyses we included all questionnaires completed
before July 2016.
The current study included patients aged 18 years and
above at inclusion in the survey. Patients who already
used a wheelchair or respiratory support at survey entry
(i.e. who had already had the “event”) were excluded
from the analyses, as were those who had completed the
survey only once (no follow-up) or had incomplete
information on the events or disease duration.
Statistical analysis
Time-dependent Cox proportional hazard models were
used to calculate the effect of ERT on the risk of using a
wheelchair or respiratory support. Models were devel-
oped separately for both outcomes.
Age was used as the time scale of the analysis, each
patient being followed from the age at inclusion in the
survey, until the date of last follow-up (censoring), or
until becoming wheelchair or ventilator dependent. ERT
was assessed as a time-dependent variable that switched
from 0 to 1 when patients started treatment. This
approach allowed patients’ to contribute both treated
and untreated person-years of follow-up to the analyses.
The following covariates were chosen a priori: disease
duration, gender and country of residence. Like ERT,
disease duration was included as a time-dependent
covariate, updating when patients started treatment.
Results are presented as hazard ratios (HRs) with 95%
confidence intervals (CIs). The proportional hazards
assumption was checked by plotting scaled Shoenfeld
residuals and correlating them with the Kaplan Meier
estimate of the survival function.
Since both analyses originate from the same popula-
tion, we used the Holm method to correct for multiple
testing [17]. Please note that the two populations over-
lap, but are not entirely the same since some of the ex-
clusions depend on whether one is assessing wheelchair
or ventilator dependency.
Statistical tests were performed using R version 3.3.1
including the survival package [18, 19]. A p-value < 0.05
was considered significant.
Results
Overall, 458 patients participated in the IPA/Erasmus MC
Pompe survey between 2002 and July 2016. The inclusion
flow-chart in Fig. 1 shows that 189 patients were eligible
for analysis of the effect of ERT on wheelchair dependency
and that 177 were eligible for analysis of respiratory sup-
port (131 patients were in both analyses). 125 patients
(27%) were excluded as they already used a wheelchair at
survey entry; 150 (33%) were excluded because they
already required respiratory support.
Table 1 compares the baseline characteristics of
patients included in the two analyses with those of all
patients participating in the IPA/Erasmus MC survey.
Overall, patients who participated in the survey (n = 458)
were equally distributed between the sexes, and entered
the survey at a median age of 47 years. Seventy percent
started ERT at some point during their follow-up.
Patients who fulfilled the inclusion criteria for our ana-
lyses had a shorter disease duration compared to those
who were excluded from the analyses (both p < 0.001).
This might be explained by the fact that patients who re-
quired a wheelchair or ventilator at survey entry had to
be excluded from the analysis. Patients included in the
analyses were also more frequently from the Netherlands
(both p < 0.001). Patients in the ventilator analysis were
more frequently female than those excluded from this
analysis (p < 0.001).
Table 2 shows the results of the time-dependent Cox
proportional hazard regression models. A total of 1120
person-years of follow-up were available for our analysis
of the effect of ERT on wheelchair use (median follow-
up 5 years, Table 1). Sixteen events occurred over 652
treated-person years and 30 events over 468 untreated-
person years. After adjustment for disease duration at
survey entry and at start of ERT, and also for sex and
country, ERT significantly reduced the risk of becoming
wheelchair dependent (hazard ratio of 0.36; CI 0.17–
0.75, Table 2). In other words, at any point during
follow-up, a treated patient had a 64% lower risk for be-
coming wheelchair dependent than an untreated patient.
Disease duration was an important predictor of becoming
wheelchair dependent: the risk for becoming wheelchair
dependent was over three times higher in those whose dis-
ease duration was over 10 years than in those with less
than 5 years. Country of residence was also significantly
associated with the risk for wheelchair use, with patients
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Fig. 1 Inclusion flowchart. *Data was incomplete if either the age at which the event occurred or the disease duration was unknown
Table 1 Characteristics of patients participating in the analysis of the effect of ERT on the use of a wheelchair and respiratory
support, and of all patients included in the IPA/Erasmus MC Pompe survey
Included in analyses All participants Survey
(n = 458)Risk of using a wheelchair (n = 189) Risk of using respiratory support (n = 177)
Female, n (%) 98 (52%) 109 (62%)* 230 (50%)
Median age at entry into
the survey, years (range)
47 (18–75) 46 (18–73) 47 (2–81)
Median age at diagnosis,
years (range)
39 (3–72) 39 (0–72) 38 (0–72)
Median disease duration at
entry, years (range)
5 (0–39)* 5 (0–31)* 7 (0–39)
Country of residence, n (%) * *
Netherlands 78 (41%) 87 (49%) 134 (29%)
United Kingdom 9 (5%) 9 (5%) 36 (8%)
United States 44 (23%) 36 (20%) 124 (27%)
Germany 26 (14%) 25 (14%) 66 (14%)
Other 32 (17%) 20 (11%) 98 (21%)
ERTa, n (%) 126 (67%) 125 (71%) 319 (70%)
Median age start ERT, years (range) 48 (13–77) 49 (13–74) 47 (3–77)
Median follow-up duration, years (range) 5 (1–14) 6 (1–14) N.A.
Events during follow-up, n (%) 46 (24%) 48 (27%) N.A.
Median age at event, years (range) 52 (21–76) 50 (24–73) N.A.
amost patients started ERT at some point during their follow-up; 57 patients in the analyses of wheelchair use and 37 in the analyses of use of respiratory support
were already receiving ERT at survey entry. *: the median/proportion was significantly different (p < 0.05) from the median/proportion in the patients who were
excluded from this analysis
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from countries other than the Netherlands, Germany, and
the US having a higher risk of using a wheelchair than
those from the Netherlands.
For the analysis of use of respiratory support, 1190
person-years were accumulated (median follow-up
6 years, Table 1). Over 661 treated person-years, 28 pa-
tients started using respiratory support, compared to 20
patients over 529 untreated person-years. We detected
no association between ERT and the risk for starting re-
spiratory support (HR 1.23; 95%CI 0.61–2.47). Longer
disease duration again tended to increase the risk for
starting respiratory support, while no significant differ-
ence was detected for sex or country of residence.
Discussion
This is the first study to provide evidence that ERT with
Alglucosidase alfa reduces the risk that adult patients with
Pompe disease will become wheelchair dependent. Using
data from an international cohort of almost 200 adult
patients, we show that, at any point in time, a patient who
received ERT had a 64% smaller probability of becoming
wheelchair dependent than an untreated patient. With
Table 2 Multivariate time-dependent Cox regression analysis of wheelchair use (A) and the need for respiratory support (B)
Events Person-years HR 95% CI p-value
A. Wheelchair use
Treatmenta
Untreated (ref) 30 468
ERT 16 652 0.36 (0.17–0.75) 0.004
Disease durationa
< 5 years (ref) 10 464
5–10 years 10 332 1.19 (0.41–3.48) 1
> 10 years 26 324 3.87 (1.55–9.61) 0.002
Sex
Male (ref) 17 583
Female 29 537 1.80 (0.88–3.69) 0.13
Country of residence
Netherlands (ref) 13 531
Germany 9 173 1.19 (0.41–3.47) 1
US 12 214 1.95 (0.73–5.22) 0.13
Other 12 202 2.99 (1.17–7.67) 0.018
B. Respiratory support
Treatmenta
Non-use (ref) 20 529
ERT 28 661 1.23 (0.61–2.47) 0.51
Disease durationa
< 5 years (ref) 11 430
5–10 years 12 319 1.12 (0.42–3.02) 1
> 10 years 25 441 2.13 (0.89–5.09) 0.051
Sex
Male (ref) 21 420
Female 27 770 0.67 (0.34–1.32) 0.18
Country of residence
Netherlands (ref) 18 599
Germany 9 189 1.28 (0.48–3.38) 1
US 13 213 2.22 (0.90–5.49) 0.10
Other 8 189 1.37 (0.52–3.62) 0.46
aTime-dependent covariates, updated at start of ERT; Italicized p-values are significant (i.e. below 0.05).
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regard to the risk for starting respiratory support, no differ-
ences could be detected.
To patients, ambulatory and respiratory status are
relevant outcomes that have a substantial impact on
quality of life [6, 20]. As sometimes decades may pass
between a patient’s first symptoms and their becoming
ventilator or wheelchair dependent, a large cohort and
long follow-up are required to study changes in these
outcomes. Similarly, any study of the effect of treatment
on these outcomes requires data that were obtained be-
fore and after start of this treatment. Our survey
uniquely meets these requirements.
Since ambulation requires sufficient muscle strength
and function, our finding that ERT reduces the risk of
becoming wheelchair dependent is in line with studies
reporting improvements in muscle strength and function
[7–15]. With regard to our inability to demonstrate an
effect of ERT on the risk for respiratory support, this
may have been due to the smaller effect of ERT on re-
spiratory muscles than on skeletal muscles, which has
been reported in several earlier studies [7, 9–11, 13].
Our analyses were corrected for disease duration,
country of residence and gender. Longer disease dur-
ation increased the risk for both wheelchair and respira-
tory support, which is in line with the progressive
character of the disease, and was also concluded from
earlier studies from the IPA/Erasmus MC Pompe survey
and our clinical studies [21–23]. The risk of wheelchair
use varied between country, potentially as a result of dif-
ferences in healthcare systems or in diagnostic delays.
Although the survey detected no differences between
gender on the risk for wheelchair use and respiratory
support, the fact that a larger proportion of men than
women were already using respiratory support at inclu-
sion in the survey suggests that there may be gender dif-
ferences in lung function. This was also suggested by
our earlier study in untreated adults, where the decline
in lung function was faster in men [23]. More research
is needed to elucidate these differences.
The IPA survey is an open cohort into which patients
are continually included. It has been shown to be a good
reflection of the clinical spectrum of adult patients with
Pompe disease [20]. Some bias may have occurred as
some patients will become lost to follow-up in such a
long-term study. In addition to correcting for con-
founders, bias was further minimized in this study
through the time dependent nature of the analysis, as
the same patient could contribute to both the treated
and untreated period.
The difference between being able to walk and needing
a wheelchair is very tangible, and ERT’s reduction of the
risk for becoming wheelchair dependent is an important
improvement. Nevertheless, a proportion of treated
patients still become wheelchair dependent at some
point in their life. Hence, while ERT shows positive clin-
ical effects in adult patients with Pompe disease, we also
conclude that there is still room for improvement.
Conclusion
ERT reduces the risk for wheelchair dependency in adult
Pompe patients. Since ambulation provides independ-
ence, we believe this is of key importance to patients. An
effect of ERT on the risk for respiratory support could
not be demonstrated.
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